Modified Risk Tobacco Product (MRTP) status represents one of the most rigorous regulatory designations a tobacco or nicotine product can receive from the United States Food and Drug Administration. For nicotine pouch manufacturers like British American Tobacco (makers of VELO), obtaining MRTP authorization could fundamentally reshape how products are marketed and perceived by consumers. But what exactly does MRTP status mean, and why does it matter for Canadian consumers who buy VELO nicotine pouches in Canada?
What Does MRTP Mean?
A Modified Risk Tobacco Product (MRTP) is any tobacco product that is sold or distributed to reduce harm or the risk of tobacco-related disease associated with commercially marketed tobacco products. Under the Family Smoking Prevention and Tobacco Control Act of 2009, the FDA established a pathway for manufacturers to apply for MRTP authorization if they can demonstrate that their product:
- Significantly reduces harm and the risk of tobacco-related disease to individual users
- Benefits the health of the population as a whole, taking into account both users and non-users
The designation allows companies to make specific reduced-risk claims in their marketing materials, something strictly prohibited for tobacco products without this authorization. This is fundamentally different from PMTA approval, which only confirms a product is appropriate for the protection of public health but does not permit reduced-risk claims.
The FDA’s MRTP Pathway
The FDA’s MRTP application process is among the most demanding regulatory pathways in the tobacco industry. Manufacturers must submit extensive scientific evidence demonstrating:
Scientific Requirements
- Toxicological data: Comprehensive analysis showing reduced exposure to harmful constituents compared to traditional tobacco products
- Clinical studies: Long-term studies demonstrating actual health benefits among users
- Population modeling: Evidence that authorization will benefit overall public health, including considerations of youth uptake and complete cessation rates
- Post-market surveillance plans: Ongoing monitoring commitments to track real-world health outcomes
The FDA reviews applications with input from its Tobacco Products Scientific Advisory Committee and typically takes several years to reach a determination. The agency can authorize modified exposure claims (reduced exposure to harmful chemicals) or modified risk claims (reduced risk of disease), with the latter requiring substantially more evidence.
Which Products Have Received MRTP Status?
As of March 2026, only a handful of products have successfully navigated the MRTP pathway. The most notable authorization came in October 2019, when the FDA granted Swedish Match’s General snus products modified risk status.
Swedish Match Snus Authorization
The FDA’s authorization for Swedish Match allowed the company to market eight General snus products with specific claims, including:
- “Using General Snus instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”
- Warnings that note the product “is not a safe alternative to cigarettes,” maintaining regulatory balance
This authorization was based on decades of Swedish epidemiological data showing dramatically lower disease rates among snus users compared to cigarette smokers. Sweden has the lowest smoking rate in Europe and correspondingly low rates of smoking-related diseases, a phenomenon many public health researchers attribute to widespread snus adoption.
Importantly, Swedish Match’s snus products contain actual tobacco, unlike modern tobacco-free nicotine pouches. This distinction is crucial when considering whether nicotine itself is carcinogenic versus the thousands of combustion byproducts in cigarette smoke.
MRTP Status for Nicotine Pouches
No nicotine pouch product has yet received MRTP authorization from the FDA, but several major manufacturers have indicated interest in pursuing this designation. The case for MRTP nicotine pouches centers on several key arguments:
Theoretical Advantages
- Tobacco-free formulation: Products like VELO contain synthetic nicotine or tobacco-derived nicotine without tobacco leaf material, eliminating tobacco-specific nitrosamines (TSNAs) found even in snus
- No combustion: Like snus, pouches avoid the most harmful aspect of cigarettes entirely
- Reduced constituent exposure: Chemical analysis shows dramatically lower levels of harmful constituents compared to cigarettes
- Established nicotine delivery: Products provide nicotine satisfaction comparable to cigarettes, potentially supporting complete switching
The science behind how VELO delivers nicotine compared to cigarettes suggests these products could theoretically support MRTP claims, but the evidentiary bar remains exceptionally high.
Regulatory Challenges
Despite these theoretical advantages, nicotine pouches face unique challenges in obtaining MRTP status:
- Limited long-term data: Modern nicotine pouches have existed for less than a decade, lacking the multi-generational epidemiological data that supported Swedish Match’s application
- Youth appeal concerns: The FDA scrutinizes whether flavored products might attract never-tobacco users, particularly youth, which could offset population-level benefits
- Dual use patterns: Evidence must show users completely switch from cigarettes rather than using pouches in situations where they cannot smoke
- Addiction perpetuation: Critics argue that while pouches may be less harmful than cigarettes, they still deliver an addictive substance and may prevent complete nicotine cessation
British American Tobacco’s MRTP Efforts
British American Tobacco (BAT), the manufacturer of VELO nicotine pouches, has publicly stated its commitment to developing a portfolio of reduced-risk products. The company has invested heavily in research supporting the harm reduction potential of its non-combustible product lines.
While BAT has not publicly disclosed a specific timeline for MRTP applications for VELO products in the United States, the company has:
- Commissioned independent toxicological studies comparing VELO to cigarettes
- Conducted clinical trials measuring biomarkers of exposure among users who switch from cigarettes to pouches
- Published research in peer-reviewed journals supporting the reduced-risk profile of oral nicotine products
- Obtained FDA marketing authorization for several VELO products through the PMTA process
The company’s “A Better Tomorrow” strategy explicitly focuses on transitioning adult smokers to products that scientific evidence indicates are less risky than continuing to smoke cigarettes. MRTP authorization would represent a significant validation of this strategy and could accelerate market growth.
What MRTP Status Would Mean for Consumers
If nicotine pouches were to receive MRTP authorization, the practical implications for consumers would include:
Marketing and Information
- Clear health comparisons: Manufacturers could make specific claims about reduced risk compared to cigarettes, helping smokers make informed decisions
- Scientific transparency: MRTP authorization requires ongoing post-market surveillance, providing continuous data about real-world health outcomes
- Regulatory legitimacy: FDA endorsement of reduced-risk claims would counter misinformation suggesting all nicotine products are equally harmful
Public Health Impact
From a population health perspective, MRTP-authorized nicotine pouches could:
- Encourage more complete switching among cigarette smokers who have not succeeded with traditional cessation methods
- Provide physicians and public health officials with an FDA-endorsed reduced-risk option to recommend to patients unwilling or unable to quit nicotine entirely
- Reduce the stigma associated with harm reduction approaches to tobacco control
- Generate high-quality longitudinal data about the health effects of long-term nicotine pouch use
Canadian Relevance
While MRTP is a United States regulatory designation with no direct legal authority in Canada, FDA decisions often influence regulatory approaches in other jurisdictions. Canadian consumers who are interested in VELO’s legal status in Canada should understand that:
- Health Canada evaluates nicotine products independently under its own regulatory framework
- FDA MRTP authorization could provide scientific evidence supporting reduced-risk arguments in Canadian regulatory discussions
- International regulatory decisions often create momentum for similar approaches elsewhere, though each country maintains its own standards
The Future of MRTP Nicotine Pouches
The question of whether nicotine pouches will receive MRTP status remains open. The pathway forward likely depends on:
- Accumulation of long-term data: As products remain on the market longer, epidemiological studies will become more robust
- Population-level outcomes: Demonstrable evidence that pouch availability actually reduces cigarette smoking at a population level
- Youth access controls: Effective prevention of youth uptake through age verification, marketing restrictions, and flavour policies
- Clinical trial results: High-quality randomized controlled trials showing health improvements among switchers
For adult smokers considering switching to nicotine pouches, the current absence of MRTP status does not necessarily indicate these products carry the same risk as cigarettes. The scientific consensus, reflected in positions from Public Health England and other organizations, supports the view that non-combustible nicotine products are substantially less harmful than smoking. MRTP status would simply provide FDA-validated marketing claims to communicate this reality more clearly.
Related Guides
Frequently Asked Questions
What does MRTP stand for?
MRTP stands for Modified Risk Tobacco Product. It is a designation granted by the United States FDA to tobacco or nicotine products that have been scientifically demonstrated to reduce harm or the risk of tobacco-related disease compared to conventional tobacco products like cigarettes.
Do any nicotine pouches have MRTP status?
As of March 2026, no nicotine pouch products have received MRTP authorization from the FDA. The only oral tobacco products with MRTP status are Swedish Match’s General snus products, which contain actual tobacco unlike modern tobacco-free nicotine pouches.
Is MRTP the same as PMTA approval?
No, MRTP and PMTA are different regulatory pathways. PMTA (Premarket Tobacco Product Application) authorization means the FDA has determined a product is appropriate for the protection of public health, but companies cannot make reduced-risk claims. MRTP authorization specifically permits manufacturers to market products with claims about reduced harm or risk compared to cigarettes, based on extensive scientific evidence.
Are nicotine pouches safer than cigarettes even without MRTP status?
While the absence of MRTP status means manufacturers cannot legally claim reduced risk, the scientific evidence strongly suggests that nicotine pouches are substantially less harmful than cigarettes. They eliminate combustion (the most harmful aspect of smoking), contain far fewer toxic chemicals, and do not expose users to the carcinogens found in tobacco smoke. However, they are not risk-free and are intended for adult smokers, not never-tobacco users.
Why is it so difficult to get MRTP authorization?
The FDA requires extraordinarily robust scientific evidence for MRTP authorization because reduced-risk claims could influence both current tobacco users and potential new users. Manufacturers must demonstrate not only that their product is less harmful to individual users, but that authorization will benefit population health overall. This requires extensive toxicological studies, clinical trials, epidemiological data, and sophisticated modeling of potential unintended consequences like youth uptake or dual use.
Does Canada have an equivalent to MRTP status?
Canada does not have a directly equivalent regulatory pathway to the FDA’s MRTP designation. Health Canada regulates nicotine products under the Tobacco and Vaping Products Act (TVPA) and generally prohibits health or reduced-risk claims on tobacco and vaping products. However, regulatory approaches continue to evolve, and international developments like FDA MRTP authorizations may inform future Canadian policy discussions.
Could VELO pouches eventually receive MRTP status?
It is theoretically possible that VELO or other nicotine pouch brands could receive MRTP authorization in the future if manufacturers can generate sufficient scientific evidence meeting the FDA’s rigorous standards. British American Tobacco has invested in research supporting the reduced-risk profile of its products, but obtaining MRTP status would require years of additional studies, clinical trials, and regulatory review. The accumulation of long-term health data as products remain on the market longer will be crucial to any future applications.